Dermal and Gynecological Acceptability (Irritability and Sensitization in the Genital Mucosa) of an Investigational Product and Evaluation of Moisture Efficacy by TEWL and Perceived Efficacy.
DERM GYN ACCEP
1 other identifier
interventional
33
0 countries
N/A
Brief Summary
To evaluate the safety of an investigational product through the verification of signs of irritability and sensitization of the genital mucosa, as well as the instrumental moisturizing efficacy by TEWL and barrier integrity analysis, in addition to the efficacy perceived by the volunteers.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 29, 2016
CompletedStudy Start
First participant enrolled
January 1, 2017
CompletedFirst Posted
Study publicly available on registry
January 2, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedJanuary 2, 2017
December 1, 2016
1 month
December 29, 2016
December 29, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Evaluation of the product's efficiency as a moisturizer through subjective evaluation
30 days
Study Arms (1)
Experimental group
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Healthy female sex with active sex life;
- Age group: between 45 and 65 years old;
- Menopause for at least six months;
- Whole skin in the region of product analysis;
- No history of reaction to products of the same category
- Understanding, agreement and signature of the Term of Free and Informed Consent.
You may not qualify if:
- Gestation or risk of gestation;
- Use of anti-inflammatory / immunosuppressive drugs (in the last 30 days and during the study);
- Active cutaneous pathologies (local and / or disseminated) in the evaluation area;
- Pathologies that cause suppression of immunity, such as diabetes, HIV, etc.;
- Endocrine pathologies such as thyroid disorders, ovarian or adrenal gland disorders;
- Other conditions considered by the investigating physician as reasonable for disqualification of the individual from the study participation.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kley Hertz S/Alead
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2016
First Posted
January 2, 2017
Study Start
January 1, 2017
Primary Completion
February 1, 2017
Last Updated
January 2, 2017
Record last verified: 2016-12